Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma

Trial Title: Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma

NCT ID: NCT06112522

Condition: Cell Carcinoma

Conditions: Official terms:
Carcinoma
Carcinoma, Basal Cell
Tirbanibulin

Conditions: Keywords:
TIRBANIBULIN

Study type: Interventional

Study phase: Phase 2

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Intervention model description: Single-Arm, Open-Label, Single Center

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Tirbanibulin
Description: Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days. Subjects with unresolved lesion at d28 or d56 or d72 or d84 will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
Arm group label: Experimental : 5 Day treatment course 1 with Tirbanibulin Ointment 1%

Other name: Tirbaso

Summary: his is a Phase 2, Single-Arm, Open-Label, Single Center, to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) not arising on the face or scalp

Detailed description: This is a pilot study aimed at studying the efficacy and tolerance of a new topical treatment regimen in BCC. The number of 50 sBCC to be treated was established based on previous studies that have investigated the effectiveness of a topical regimen in sBCC. Considering that approximately 10% of BCCs will be wrongly included or not evaluable or will present with a deviation protocol major, a total of 55 sBCC will be included in the study.Inclusion Criteria : - Age > 18 years - Histologically confirmed, primary, previously untreated, superficial basal cell carcinoma (sBCC) not arising on the face or scalp, ≤ 15 mm (large axis) Exclusion Criteria : - BCC of the face or scalp - BCC of non-superficial subtype - BCC with large axis > 15mm - Relapsing BCC - Allergy to treatment - Treatment with cryotherapy, imiquimod, PDT, or radiotherapy in the BCC area during the 6 months prior to the screening visit. Visits : 1) Selection visit = V0: if the patient meets the selection criteria, oral and written information will be given to him. If the patient signs the consent during this consultation, the inclusion visit will be carried out at the same time. 2) Inclusion visit and start of treatment = V1 (D1): for patients who have not signed their consent at the previous visit, consent will be collected • Verification of inclusion and non-inclusion criteria • Collection of medical and surgical history • Collection of previous and concomitant treatments • Clinical evaluation by visual inspection: measurement of the long axis, calculation of the surface to be treated (maximum treated surface for all sBCC should not exceed > 25 cm2) • Realization of a layer with the limits of the lesion • Clinical photos • Examination by LC-OCT • Dispensing of Tirbanibulin for the treatment cycle (1 tube for up to 3 sBCC) • Explanation of the mode of application to the patient • First application performed on site • Giving the patient a notebook to record the applications of the product and local skin reactions. 3) Follow-up visit +/- retreatment = V2 (D28 ± 2 d) • Collection of adverse events and changes in concomitant treatments • Collection of local skin reactions in the patient notebook • Evaluation of local skin reactions • Clinical evaluation and by LC-OCT -> In case of cure clinically and by LC-OCT (complete remission, CR) end of the study for the patient -> In the absence of CR processing as in V1 -> in case of a wound at the application site, the study will end for the patient and he will be treated according to standard recommendantions for• sBCC 4) Additional follow-up visits +/- retreatment = V3 (D56±2 days), V4 (D84+/-2d) : these visits will be conducted identically to V2. 5) Short-term efficacy visit = V5 (D112 +/- 2d): same as V2 w/o treatment with Tirbanibulin. Patients not in CR will terminate the study and will be treated according to standard recommendations for sBCC. 6) Long-term efficacy visit = V6 (M12): same as V2 w/o treatment with Tirbanibulin. All patients will terminate the study. Patients with relapse of their BCC will be treated according to standard recommendations for sBCC.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Age > 18 years - Histologically confirmed, - primary, previously untreated, - superficial basal cell carcinoma (sBCC) not arising on the face or scalp, ≤ 15 mm (large axis) Exclusion Criteria: - BCC of the face or scalp - BCC of non-superficial subtype - BCC with large axis > 15mm - Relapsing BCC - Allergy to treatment - Treatment with cryotherapy, imiquimod, PDT, or radiotherapy in the BCC area during the 6 months prior to the screening visit

Gender: All

Gender based: Yes

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: CHU de Nice - Hôpital de l'Archet

Address:
City: Nice
Zip: 06200
Country: France

Status: Recruiting

Contact:
Last name: Philippe Bahadoran, PhD

Phone: +33492036223
Email: bahadoran.p@chu-nice.fr

Investigator:
Last name: Philippe Bahadoran
Email: Principal Investigator

Start date: February 16, 2024

Completion date: December 1, 2025

Lead sponsor:
Agency: Centre Hospitalier Universitaire de Nice
Agency class: Other

Source: Centre Hospitalier Universitaire de Nice

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06112522